| Stroke and atherothrombosis: an update on the role of antiplatelet therapy. | |
| | |
MedLine Citation:
|
PMID: 18705896 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atherothrombosis is responsible for most acute ischemic manifestations of atherosclerotic disease, including stroke. Individuals with evidence of atherothrombotic disease in one vascular bed have a significant risk of recurrence and show increased vulnerability over time for other manifestations elsewhere in the vasculature. Ischemic event rates for asymptomatic patients with multiple atherothrombotic risk factors appear to be similar to those in patients with documented cardiovascular disease. For example, diabetes mellitus and obesity are found at alarmingly high rates in patients with prior cardiovascular events, including stroke or transient ischemic attacks. Antiplatelet therapy is a key component of atherothrombotic event prevention. The results of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) study showed that while dual antiplatelet therapy with aspirin and clopidogrel may not play a role in primary prevention, post hoc analysis alluded to the possibility of benefit for dual antiplatelet therapy in certain populations of stroke patients. We examined current recommendations for the prevention of atherothrombotic events, focusing on the role of oral antiplatelet agents in patients with ischemic stroke. |
| | |
Authors:
|
Andrei V Alexandrov; Peter Alagona |
Related Documents
:
|
9077506 - Hyperkinetic movement disorders during and after acute stroke: the lausanne stroke regi... 20537496 - An unfavorable dietary pattern is associated with symptomatic ischemic stroke and carot... 8422846 - Risk factors for developing seizures after a stroke. 20444626 - Neurovascular complications of cocaine use at a tertiary stroke center. 15925866 - Role of interleukin-1beta in the development of malnutrition in chronic renal failure p... 22165676 - Credibility of the measurement of serum ferritin and transferrin receptor as indicators... |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: International journal of stroke : official journal of the International Stroke Society Volume: 3 ISSN: 1747-4949 ISO Abbreviation: - Publication Date: 2008 Aug |
Date Detail:
|
Created Date: 2008-08-18 Completed Date: 2008-11-18 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101274068 Medline TA: Int J Stroke Country: England |
Other Details:
|
Languages: eng Pagination: 175-81 Citation Subset: IM |
Affiliation:
|
Comprehensive Stroke Center, University of Alabama, Birmingham, AL 35294-0017, USA. avalexandrov@att.net |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Atherosclerosis
/
drug therapy,
prevention & control* Delayed-Action Preparations Dipyridamole / administration & dosage, therapeutic use* Embolism, Cholesterol / drug therapy, prevention & control* Humans Platelet Aggregation Inhibitors / therapeutic use* Risk Assessment Risk Factors Stroke / drug therapy, prevention & control* |
| Chemical | |
Reg. No./Substance:
|
0/Delayed-Action Preparations; 0/Platelet Aggregation Inhibitors; 58-32-2/Dipyridamole |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Ischemic perinatal stroke: challenge and opportunities.
Next Document: Setting up an acute stroke service.